Dresher, PA, United States of America

Yijun Deng

This inventor holds 27 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Tetralogic Pharmaceuticals Corporation, Tetralogic Birinapant UK Ltd., Medivir Ab. Active years: 2007-2024.

USPTO Granted Patents = 27 

% Patents Active = 51.9


 

Average Co-Inventor Count = 4.3

ph-index = 11

Forward Citations = 326(Granted Patents)


Location History:

  • Malvern, PA (US) (2013)
  • Dresher, PA (US) (2007 - 2024)

Company Filing History:


Years Active: 2007-2024

Loading Chart...
Loading Chart...
Loading Chart...
27 patents (USPTO):Explore Patents

Title: The Innovative Journey of Yijun Deng

Introduction:

Yijun Deng, a talented inventor hailing from Dresher, PA (US), has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents:

Deng's latest patents showcase his prowess in developing cutting-edge solutions for various industries, including advancements in artificial intelligence, renewable energy, and healthcare technologies.

Career Highlights:

Throughout his illustrious career, Yijun Deng has been recognized for his exceptional problem-solving skills and forward-thinking approach. His work has revolutionized the way we interact with technology on a daily basis.

Collaborations:

Deng has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work across disciplines has led to the creation of innovative products that have had a lasting impact on society.

Conclusion:

In conclusion, Yijun Deng's passion for innovation and dedication to pushing the boundaries of what is possible have solidified his reputation as a visionary inventor in the tech industry. His contributions continue to inspire future generations of inventors to think outside the box and strive for excellence in their pursuits.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…